UnitedHealthcare prostate procedures Policy Update

Coverage Criteria and Clinical Rationale

inv-01: Transurethral ablation: Covered when meeting InterQual

Covered when ALL of the following are met:

Transurethral ablation - coverage stance: Transurethral ablation of the prostate is proven and medically necessary in certain circumstances; for specific medical necessity clinical coverage criteria, refer to the InterQual CP: Procedures, Prostatectomy, Transurethral Ablation.

Refer to InterQual criteria for specifics

inv-02: Cryoablation: Covered for recurrent prostate cancer

Covered when ALL of the following are met:

Cryoablation - recurrent cancer: Cryoablation of the prostate is proven and medically necessary for recurrent prostate cancer diagnosed by biopsy; for medical necessity clinical coverage criteria, refer to the InterQual CP: Procedures, Cryoablation, Prostate.

Unproven and not medically necessary for initial treatment and other indications

inv-03: PUL: Covered per FDA labeled indications

Covered when ALL of the following are met:

PUL - FDA labeled indications: Prostatic urethral lift (PUL) is proven and medically necessary when performed according to FDA labeled indications: treating symptoms due to urinary outflow obstruction secondary to BPH, including lateral, with or without median lobe hyperplasia, in men 45 years of age or older; and none of the following are present: prostate volume > 100 cc; urinary tract infection; urethral conditions preventing insertion of the delivery system into the bladder; urinary incontinence due to incompetent sphincter; current gross hematuria.age >= 45 years; prostate volume <= 100 cc

Follow Instructions for Use and FDA contraindications/warnings

inv-04: Water vapor thermotherapy: Covered when meeting InterQual

Covered when ALL of the following are met:

Water vapor thermotherapy - coverage: High-energy water vapor thermotherapy for treatment of BPH is proven and medically necessary in certain circumstances; for medical necessity clinical coverage criteria, refer to the InterQual CP: Procedures, Prostatectomy, Transurethral Ablation.

Not medically necessary for treatment of malignant prostate tissue or other unproven indications

inv-05: Transurethral water jet ablation: Covered for LUTS from BPH

Covered when ALL of the following are met:

Water jet ablation - coverage: Transurethral water jet ablation of the prostate is proven and medically necessary for resection and removal of prostate tissue to treat lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia.

Transurethral water jet ablation for treatment of malignant prostate tissue and all other indications not listed as proven is unproven and not medically necessary

inv-06: Prostate artery embolization: Covered for specific indications

Covered when ANY of the following are met:

PAE - covered indications: Prostate artery embolization (PAE) is proven and medically necessary for individuals meeting at least one of the following: (1) BPH patients who are ineligible for other procedures due to surgical constraints (e.g., prostate size) or anesthesia risk (e.g., comorbidities); OR (2) persistent gross hematuria originating from the prostate.

PAE is unproven and not medically necessary for other indications

inv-07: Procedures considered unproven / not medically necessary

These procedures are NOT medically necessary (unproven) when performed for all indications due to insufficient evidence of safety and/or efficacy:

Unproven procedures - list: The following are unproven and not medically necessary due to insufficient evidence of safety and/or efficacy: transperineal focal laser ablation; insertion of a temporary prostatic urethral stent; transperineal laser ablation (TPLA); ablation of malignant prostate tissue by magnetic field induction; transurethral drug-coated balloon dilation; transurethral thermal ultrasound ablation (TULSA).

Routine use should be restricted to clinical trials or prospective registries where noted

inv-08: Cryoablation (evidence summary)

Evidence summary (key points):

Cryoablation evidence summary: Cryoablation evidence is dominated by observational studies (single-arm and retrospective series) for primary and salvage prostate cancer with heterogeneous outcome reporting; no RCTs identified and additional high-quality research is needed.

Heterogeneity in oncologic outcome definitions and inconsistent reporting limit conclusions

inv-09: Prostatic Urethral Lift (PUL/UroLift)

Clinical trial population and outcomes (key points):

PUL RCT population and outcomes: PUL (UroLift) randomized sham-controlled trial enrolled men ≥50 years with IPSS >12, Qmax ≤12 mL/s, and prostate volume 30–80 cc; PUL improved IPSS, QOL, BPHII and Qmax with durable effects to 5 years and preserved sexual function. Evidence base includes additional comparative trials showing symptom improvement but TURP may provide greater symptom reduction on some endpoints.

Refer to trial inclusion thresholds when documenting candidates

inv-10: Transurethral Waterjet Ablation (Aquablation)

Evidence summary (key points):

Aquablation evidence: Aquablation (transurethral waterjet ablation) has randomized controlled trial evidence comparing it to TURP with follow-up to 5 years showing similar IPSS improvements and potential advantages for ejaculatory preservation; additional single-arm and registry studies support short- to intermediate-term benefit across prostate sizes, though long-term comparative evidence remains limited.prostate volume typically studied 20–150 cc; EAU suggests 30–80 mL for alternative to TURP

Document prostate size and baseline IPSS/Qmax to align with trial populations

inv-11: Prostate Artery Embolization (PAE)

Evidence summary (key points):

PAE evidence: PAE provides short-term procedural benefits (less blood loss, shorter hospitalization) but TURP consistently provides greater long-term functional benefit; available RCTs show inferior functional outcomes and higher retreatment rates for PAE (e.g., 21% required TURP within 2 years in one RCT). Additional RCTs with >2 years follow-up are needed.

PAE may be considered for patients who are poor surgical candidates or have persistent prostatic hematuria

inv-12: PAE — Coverage considerations

Coverage considerations informed by evidence:

PAE - coverage considerations: Evidence is insufficient to support equivalence of PAE to TURP for long-term functional outcomes; PAE may be offered for individuals who are ineligible for established surgical procedures due to surgical constraints or anesthesia risk, or for persistent gross prostatic hematuria after medical management.

Require documentation of surgical ineligibility, discussion of alternatives, and shared decision-making

inv-13: TPLA/FLA — Coverage considerations

Coverage considerations and limitations:

TPLA/FLA — coverage considerations: Transperineal focal laser ablation (TPLA/FLA) has insufficient and conflicting oncologic outcome data with short follow-up; randomized trials for TPLA in BPH have shown inferiority to TURP for some efficacy endpoints. Use should be limited to clinical trials or prospective registries.

Document tumor characteristics and trial enrollment when applicable

inv-14: Coverage summary by procedure

Summaries by procedure (evidence-informed):

TPLA summary: TPLA: insufficient long-term evidence; RCTs demonstrate inferiority to TURP for efficacy though sexual adverse events may be lower; consider investigational or limited coverage in trials.

Temporary urethral stents / iTind: mixed RCT results and single-arm studies with limited durability data; evidence considered insufficient/inconclusive for routine coverage.

Consider limited coverage only within specified study criteria or registries

Magnetic field induction ablation: Ablation of malignant prostate tissue by magnetic field induction: evidence limited to a small Phase I trial with feasibility and safety concerns; investigational and not supported for routine clinical use.

Transurethral drug-coated balloon (Optilume): Optilume: randomized sham-controlled evidence shows symptom improvement sustained to up to 4 years, but absence of comparative trials to established therapies limits definitive coverage conclusions; may require prior authorization and documentation of trial-like eligibility and outcomes.

inv-15: Guideline-aligned coverage considerations

Guideline-aligned considerations to inform coverage decisions:

Guideline-aligned coverage considerations: Coverage decisions should align with professional guideline statements: offer PUL, water vapor therapy, PAE, and aquablation within stated prostate size and anatomy limits; restrict routine use of whole-gland or focal ablation for prostate cancer outside clinical trials per AUA/ASTRO guidance.

Derived from AUA, AUA/ASTRO, EAU, SIR statements

inv-16: Covered/Proven or Recommended Procedures

Procedures and alternatives identified as covered/proven or recommended by guidelines:

EAU/Guideline recommended procedures: EAU and other guideline statements identify enucleation (Tm:YAG, HoLEP), diode laser enucleation, aquablation (for prostate volume 30–80 mL), and select use of PAE in highly trained centers as acceptable alternatives to TURP for appropriate patients.prostate volume 30-80 mL for aquablation

See guideline references

inv-17: Not Medically Necessary / Unproven Procedures

Procedures explicitly listed as not medically necessary / unproven in the policy revision:

Explicitly unproven/not medically necessary: The July 1, 2025 revision lists the following as unproven and not medically necessary: transperineal focal laser ablation; insertion of temporary prostatic urethral stent; transperineal laser ablation (TPLA); ablation of malignant prostate tissue by magnetic field induction; transurethral drug-coated balloon dilation; and transurethral thermal ultrasound ablation (TULSA).

Policy revision adds TULSA to unproven list

inv-18: Eligibility Clarifications

Eligibility clarifications and documentation expectations:

PAE eligibility clarification: PAE is proven and medically necessary for individuals with BPH who are ineligible for other procedures due to surgical constraints (e.g., prostate size) or anesthesia risk (e.g., comorbidities); documentation should include reason for ineligibility, prior conservative and medical management, prostate volume, and imaging confirming prostatic origin of symptoms or hematuria.

Require shared decision-making documentation and discussion of alternatives (e.g., TURP)

The policy explicitly identifies treatment of malignant prostate tissue with minimally invasive transurethral or focal technologies as unproven and not medically necessary when used for indications outside the policy’s listed proven uses. Examples cited include water vapor thermotherapy, transurethral water jet ablation, transperineal focal laser ablation (TPLA), magnetic field induction ablation, and transurethral thermal ultrasound ablation (TULSA), all of which lack sufficient evidence of safety and/or efficacy for malignant disease and other unlisted indications.

When evaluating claims or prior authorization requests, procedures directed at malignant prostate tissue should be considered not medically necessary unless the submission documents an evidence-supported indication explicitly listed as proven in this policy or the procedure is performed within an approved clinical trial or registry with appropriate documentation.

The policy notes that for high-energy water vapor thermotherapy there were no peer-reviewed original data publications identified for treatment of malignant prostate tissue; accordingly, use of this modality for malignant indications is classified as unproven and not medically necessary.

For benign indications Rezūm (high-energy water vapor thermotherapy) remains a covered option when InterQual criteria are met, but the policy separates that approved use from any application to malignant prostate tissue because of the absence of primary literature supporting cancer treatment.

Systematic reviews and guideline statements summarized in the policy conclude that routine use of focal therapy (including focal laser ablation) for localized prostate cancer is not recommended outside of clinical trials or prospective comparative studies. Evidence is heterogeneous, of limited quality, and lacks long-term oncologic outcomes, supporting restriction of focal therapies to research settings.

The AUA/ASTRO guidance specifically advises clinicians to inform patients that whole-gland or focal ablation procedures lack high-quality comparative data and should not be recommended routinely outside clinical trials, reinforcing the policy’s stance.

Several procedures are listed as having insufficient evidence to establish safety and long-term effectiveness and therefore are classified as unproven and not medically necessary. These include transperineal focal laser ablation (TPLA/FLA) where randomized trials show inferiority to TURP for some endpoints, temporary urethral stents (including mixed RCT findings and limited comparative data), and ablation of malignant prostate tissue by magnetic field induction which is limited to a small Phase I trial.

The policy also lists other novel or device-based interventions (for example, transurethral drug-coated balloons) for which evidence is limited, short-term, or lacks comparison to established therapies; such procedures are therefore considered investigational or not medically necessary pending stronger comparative data.

The American Urological Association (AUA) together with the American Society for Radiation Oncology (ASTRO) state that clinicians should inform patients considering whole-gland or focal ablation that there are insufficient high-quality comparative data versus established treatments and that these procedures should not be recommended outside of a clinical trial.

This guideline-based view supports the policy’s approach of restricting routine clinical use of whole-gland or focal ablation for localized prostate cancer to research settings and carefully selected cases with trial enrollment or prospective registry documentation.

Transurethral water jet ablation (Aquablation) is covered for treatment of LUTS due to benign prostatic hyperplasia when performed for the approved benign indications, but the policy clarifies that use for malignant prostate tissue and for any other indications not listed as proven is unproven and not medically necessary due to insufficient evidence of safety and efficacy.

Providers should ensure the indication aligns with the proven policy statements (LUTS/BPH) and that any request to treat malignant disease is not supported by this coverage policy.

The policy enumerates a comprehensive list of procedures and indications classified as unproven and not medically necessary. Notable entries include: treatment of malignant prostate tissue with water vapor thermotherapy or transurethral water jet ablation; transperineal focal laser ablation (TPLA/FLA); insertion of temporary prostatic urethral stents; ablation of malignant prostate tissue by magnetic field induction; transurethral drug-coated balloon dilation (Optilume) for indications lacking comparative evidence; and transurethral thermal ultrasound ablation (TULSA).

These items are identified because of limited or low-quality evidence, lack of randomized comparative data showing long-term safety and effectiveness, or absence of peer-reviewed data for specific malignant indications; as a result they are designated not medically necessary outside of clinical trial settings or pending higher-quality evidence.

The policy states that prostate artery embolization (PAE) should be considered investigational or not medically necessary when used routinely as an alternative to established surgical therapies (e.g., TURP) because comparative evidence shows inferior functional outcomes and higher retreatment rates in some studies; however, it also recognizes specific situations where PAE is proven and medically necessary.

Specifically, PAE is considered proven and medically necessary for individuals with BPH who are ineligible for other procedures due to surgical constraints (for example, prostate size) or anesthesia risk (for example, comorbidities), and for persistent gross hematuria originating from the prostate. Requests for routine substitution of PAE for standard surgical options should be supported by documentation of contraindications or high surgical risk.

Ablation of malignant prostate tissue by magnetic field induction (magnetic nanoparticle ablation) is identified as investigational due to extremely limited evidence — principally a small Phase I trial — and reported safety or feasibility concerns in that early work. The policy therefore classifies this approach as unproven and not medically necessary.

Similarly, focal laser approaches (TPLA/FLA) lack robust long-term oncologic outcome data and have reported mixed or concerning comparative findings; these limitations underpin the noncoverage stance outside of clinical trials.

The document notes that evidence is insufficient regarding safety, efficacy, and long-term outcomes for certain emerging ablative procedures — for example TULSA — where studies to date are single-arm or early-phase with small participant numbers and short follow-up, limiting confidence in durability and oncologic control.

Accordingly, TULSA is listed among procedures considered unproven and not medically necessary for routine clinical use outside trials, and coverage requests should reflect this limitation.

Transurethral thermal ultrasound ablation (TULSA) is explicitly added to the policy’s list of procedures deemed unproven and not medically necessary. Although early-phase data (for example the TACT pivotal single-arm trial) report feasibility and short-term outcomes, the policy emphasizes the lack of randomized comparative evidence and limited long-term follow-up as reasons for noncoverage outside research settings.

Providers requesting authorization for TULSA should include trial enrollment documentation or prospective registry participation to support consideration; otherwise, routine coverage is not supported by the policy.

Applicable Codes and Coding Notes

Applicable CPT/Category III codes (group 1)CPT

0421T	Transurethral waterjet ablation of prostate, including control of post-operative bleeding, including ultrasound guidance, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included when performed).
0582T	Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance.

Applicable CPT/Category III codes (group 2)CPT

0619T	Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed.
0655T	Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound.
0714T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume less than 50mL.
0738T	Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination.
0739T	Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation.
0867T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume greater or equal to 50mL.

Applicable traditional CPT codesCPT

37243	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural road mapping, and imaging guidance necessary to complete the intervention: for tumors, organ ischemia, or infarction (when performed on prostate tissue).
51721	Insertion of transurethral ablation transducer for delivery of thermal ultrasound for prostate tissue ablation, including suprapubic tube placement during the same session and placement of an endorectal cooling device, when performed.
52441	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant.
52442	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; each additional permanent adjustable transprostatic implant (List separately in addition to code for primary procedure).
53850	Transurethral destruction of prostate tissue; by microwave thermotherapy.
53852	Transurethral destruction of prostate tissue; by radiofrequency thermotherapy.
53854	Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy.
53855	Insertion of a temporary prostatic urethral stent, including urethral measurement.
53865	Cystourethroscopy with insertion of temporary device for ischemic remodeling (i.e., pressure necrosis) of bladder neck and prostate.
53866	Catheterization with removal of temporary device for ischemic remodeling (i.e., pressure necrosis) of bladder neck and prostate.

1–10 of 13

1/2

Codes mentionedmixed

No codes listed

Applicable/changed CPT codesCPT

51721	CPT added per policy revision
53865	CPT added per policy revision
53866	CPT added per policy revision
55881	CPT added per policy revision
55882	CPT added per policy revision
55874	CPT removed per policy revision

Prostate volume contraindication for PUL (> 100 cc)

ContraindicationProstate volume > 100 cc is a contraindication to PUL (UroLift) per FDA labeled indications

Age requirementIndicated for men 45 years of age or older

Other absolute exclusionsActive urinary tract infection, urethral conditions preventing delivery system insertion, urinary incontinence due to incompetent sphincter, current gross hematuria

Common trial inclusion thresholds (age, IPSS, Qmax, prostate volume)

Typical age thresholdAge ≥ 50 years commonly used in trials

Prior Authorization, Documentation & Denial Risk

Prior Authorization

InterQual-based prior authorization for select procedures

Some transurethral and other prostate procedures require prior authorization. UnitedHealthcare uses InterQual® as the primary medical/surgical criteria; procedures not meeting InterQual or other applicable coverage criteria may be denied. Prior authorization is recommended for select procedures to ensure documented medical necessity and that required conservative therapies and alternative options have been considered.

InterQual-based prior authorization may be required for transurethral ablation procedures and other prostate surgeries.
Listing of a code in this policy does not guarantee coverage; federal, state, or contractual requirements govern coverage decisions.

Prior Authorization

Prior authorization recommended for limited-evidence procedures

Prior authorization is recommended for a range of emerging or limited-evidence procedures for BPH and localized prostate cancer to allow review of documentation supporting patient selection, prior therapies, and discussion of alternatives. Requesting authorization helps reduce risk of claim denials where evidence is insufficient or prerequisites are missing.

Background and Definitions

Benign prostatic hyperplasia (BPH) is common in men over age 50 and produces lower urinary tract symptoms (LUTS) ranging from mild bother to significant obstruction. Management spans conservative care (lifestyle modification and pharmacotherapy) for mild cases to minimally invasive or surgical interventions for moderate-to-severe or refractory symptoms.

This policy addresses a spectrum of prostate procedures — including transurethral ablation, cryoablation, prostatic urethral lift (PUL/UroLift), high-energy water vapor thermotherapy (Rezūm), transurethral waterjet ablation (Aquablation), prostate artery embolization (PAE), focal laser approaches (TPLA/FLA), temporary stents (iTind), drug-coated balloons (Optilume), magnetic nanoparticle ablation, and TULSA — and distinguishes which therapies are considered proven and medically necessary for specified indications versus those that are investigational or not medically necessary due to limited or low-quality evidence.

Definition — Cryoablation

DefinitionCryoablation (cryotherapy) — transrectal ultrasound–guided probes deliver extreme cold gas through probes to freeze and destroy prostate tissue

Clinical usesEvaluated for primary and salvage treatment of prostate cancer; evidence largely from observational studies

Outcome measuresStudies report disease-specific survival, biochemical recurrence (Phoenix definition), PSA nadir, and various functional complications

Policy Revision History

07/01/2025policy_revisionLatest

Multiple substantive changes: removed coverage criteria for transperineal placement of biodegradable material; revised PUL coverage wording to 'lateral, with or without median lobe hyperplasia'; clarified transurethral water jet ablation is unproven and not medically necessary for malignant prostate tissue and other non‑proven indications; clarified PAE wording to specify BPH patients ineligible for other procedures; added TULSA to list of unproven/not medically necessary procedures; updated supporting information sections.

OpenPayer

Prostate Surgeries and Interventions (for Ohio Only)

Coverage Criteria and Clinical Rationale

Applicable Codes and Coding Notes

Prior Authorization, Documentation & Denial Risk

Background and Definitions

Policy Revision History